Pfizer Agrees to Settle More than 10,000 Zantac Cancer Suits
Financial details of accords not immediately available Users claim Pfizer, GSK knew heartburn drug posed cancer risk
A researcher prepares to test a bottle of Zantac 150 at the Valisure lab in New Haven, Connecticut, in 2022.
Photographer: Gabby Jones/BloombergPfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.
The agreements cover cases in state courts across the US but don’t completely resolve the company’s exposure to Zantac claims, according to the people, who spoke on the condition of anonymity because they weren’t authorized to discuss the settlement publicly. Financial details of the accords weren’t immediately available.
No comments:
Post a Comment